Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce ...

Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Polyethylenimine (PEI)-assisted transfection is a mainstay in upstream processing (USP) for viral vector manufacturing. But recent developments are shifting it from a ...

Bioprocessing comprises the integrated design, optimisation and control of biological systems used to produce commercially valuable products. It harnesses living cells, enzymes or whole organisms, ...